Innocare's TYK2 Inhibitor Soficitinib Meets Primary Endpoint in Phase II Vitiligo Study

Stock News07-16 16:47

Clinical trial results for Innocare Pharma Limited (ASX: 688428) show its investigational drug has successfully achieved its primary objective in a mid-stage study.

The company announced that the Phase II portion of its adaptive Phase II/III clinical study for soficitinib (ICP-332) in treating non-segmental vitiligo (NSV) has met the primary endpoint, delivering positive top-line results.

Soficitinib is a novel, highly selective oral tyrosine kinase 2 (TYK2) inhibitor developed by Innocare. The TYK2 enzyme is a member of the Janus kinase (JAK) family and plays a critical role in signaling pathways downstream of interleukin (IL)-12/IL-23 family cytokine receptors and type I interferon (IFN) receptors.

These signaling pathways are involved in regulating the function of various immune cells, including T helper 17 (Th17) cells, T helper 1 (Th1) cells, B cells, and myeloid cells. They are implicated in the development and progression of several autoimmune and chronic inflammatory diseases, such as psoriasis, inflammatory bowel disease, systemic lupus erythematosus, and atopic dermatitis.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119468233?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 16:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119468233","market":"sh","top_or_hot":-1,"title":"Innocare's TYK2 Inhibitor Soficitinib Meets Primary Endpoint in Phase II Vitiligo Study","media":"Stock News","content":"<p>Clinical trial results for <b>Innocare Pharma Limited</b> (<b>ASX: 688428</b>) show its investigational drug has successfully achieved its primary objective in a mid-stage study.<br><br>The company announced that the Phase II portion of its adaptive Phase II/III clinical study for soficitinib (ICP-332) in treating non-segmental vitiligo (NSV) has met the primary endpoint, delivering positive top-line results.<br><br>Soficitinib is a novel, highly selective oral tyrosine kinase 2 (TYK2) inhibitor developed by Innocare. The TYK2 enzyme is a member of the Janus kinase (JAK) family and plays a critical role in signaling pathways downstream of interleukin (IL)-12/IL-23 family cytokine receptors and type I interferon (IFN) receptors.<br><br>These signaling pathways are involved in regulating the function of various immune cells, including T helper 17 (Th17) cells, T helper 1 (Th1) cells, B cells, and myeloid cells. They are implicated in the development and progression of several autoimmune and chronic inflammatory diseases, such as psoriasis, inflammatory bowel disease, systemic lupus erythematosus, and atopic dermatitis.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innocare's TYK2 Inhibitor Soficitinib Meets Primary Endpoint in Phase II Vitiligo Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnocare's TYK2 Inhibitor Soficitinib Meets Primary Endpoint in Phase II Vitiligo Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-16 16:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Clinical trial results for <b>Innocare Pharma Limited</b> (<b>ASX: 688428</b>) show its investigational drug has successfully achieved its primary objective in a mid-stage study.<br><br>The company announced that the Phase II portion of its adaptive Phase II/III clinical study for soficitinib (ICP-332) in treating non-segmental vitiligo (NSV) has met the primary endpoint, delivering positive top-line results.<br><br>Soficitinib is a novel, highly selective oral tyrosine kinase 2 (TYK2) inhibitor developed by Innocare. The TYK2 enzyme is a member of the Janus kinase (JAK) family and plays a critical role in signaling pathways downstream of interleukin (IL)-12/IL-23 family cytokine receptors and type I interferon (IFN) receptors.<br><br>These signaling pathways are involved in regulating the function of various immune cells, including T helper 17 (Th17) cells, T helper 1 (Th1) cells, B cells, and myeloid cells. They are implicated in the development and progression of several autoimmune and chronic inflammatory diseases, such as psoriasis, inflammatory bowel disease, systemic lupus erythematosus, and atopic dermatitis.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688428","symbol_name":"诺诚健华","start_time":0,"source_url":"","article_id":"1119468233","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119468233","pubTimestamp":1784191679,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Clinical trial results for Innocare Pharma Limited (ASX: 688428) show its investigational drug has successfully achieved its primary objective in a mid-stage study.The company announced that the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688428":"诺诚健华","BK0239":"医药制造","09969":"诺诚健华","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"诺诚健的TYK2抑制剂索菲替尼在II期白癜风研究中达到主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688428":1,"09969":1},"content_text":"Clinical trial results for Innocare Pharma Limited (ASX: 688428) show its investigational drug has successfully achieved its primary objective in a mid-stage study.The company announced that the Phase II portion of its adaptive Phase II/III clinical study for soficitinib (ICP-332) in treating non-segmental vitiligo (NSV) has met the primary endpoint, delivering positive top-line results.Soficitinib is a novel, highly selective oral tyrosine kinase 2 (TYK2) inhibitor developed by Innocare. The TYK2 enzyme is a member of the Janus kinase (JAK) family and plays a critical role in signaling pathways downstream of interleukin (IL)-12/IL-23 family cytokine receptors and type I interferon (IFN) receptors.These signaling pathways are involved in regulating the function of various immune cells, including T helper 17 (Th17) cells, T helper 1 (Th1) cells, B cells, and myeloid cells. They are implicated in the development and progression of several autoimmune and chronic inflammatory diseases, such as psoriasis, inflammatory bowel disease, systemic lupus erythematosus, and atopic dermatitis.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119468233","isCrawlerRequest":true}